Trial Profile

A Phase IIb Study of RAMucirumab in Combination With TAS102 vs. TAS102 Monotherapy in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ramucirumab (Primary) ; Tipiracil/trifluridine (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use
Acronyms RAMTAS

Most Recent Events

09 Aug 2024 Status changed from active, no longer recruiting to completed.
20 Feb 2023 Status changed from recruiting to active, no longer recruiting.
08 Jun 2021 Interim results (n=80) of safety analysis from patients enrolled in arm A and arm B presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com